Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ANIK 
Anika Therapeutics Inc (ANIK)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/27/2025: ANIK (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $15.5
1 Year Target Price $15.5
| 2 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -4% | Avg. Invested days 45 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 144.33M USD | Price to earnings Ratio - | 1Y Target Price 15.5 |
Price to earnings Ratio - | 1Y Target Price 15.5 | ||
Volume (30-day avg) 3 | Beta 0.62 | 52 Weeks Range 7.87 - 24.84 | Updated Date 10/26/2025 |
52 Weeks Range 7.87 - 24.84 | Updated Date 10/26/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.9 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-10-29 | When Before Market | Estimate -0.11 | Actual - |
Profitability
Profit Margin -52.93% | Operating Margin (TTM) -14.81% |
Management Effectiveness
Return on Assets (TTM) -2.4% | Return on Equity (TTM) -7.23% |
Valuation
Trailing PE - | Forward PE 50.76 | Enterprise Value 103313980 | Price to Sales(TTM) 1.26 |
Enterprise Value 103313980 | Price to Sales(TTM) 1.26 | ||
Enterprise Value to Revenue 0.9 | Enterprise Value to EBITDA -72.65 | Shares Outstanding 14418090 | Shares Floating 10362570 |
Shares Outstanding 14418090 | Shares Floating 10362570 | ||
Percent Insiders 4.88 | Percent Institutions 89.44 |
Upturn AI SWOT
Anika Therapeutics Inc
Company Overview
History and Background
Anika Therapeutics Inc. was founded in 1992. It is a global medical technology company focused on creating and delivering innovative regenerative solutions that address unmet needs in pain management, tissue regeneration, and wound care.
Core Business Areas
- Joint Preservation & Restoration: Products include hyaluronic acid (HA)-based therapies for osteoarthritis (OA) pain management, as well as surgical solutions for joint preservation and restoration. This also contains HA products for viscosupplementation.
- Wound Care & Dermal: Products targeting wound healing and skin regeneration using innovative technologies.
- Surgical: Products for soft tissue repair and regeneration in various surgical procedures.
Leadership and Structure
The leadership team includes Cheryl R. Blanchard, Ph.D. (President and CEO). The organizational structure is typical of a publicly traded company, with a board of directors overseeing management.
Top Products and Market Share
Key Offerings
- MONOVISC: A single-injection HA viscosupplement for OA knee pain. Competitors include Sanofi (SYNVISC), Zimmer Biomet (Gel-One), and Johnson & Johnson (ORTHOVISC). Market share data is difficult to pinpoint exactly, but MONOVISC is a significant player in the single-injection HA market.
- ORTHOVISC: A multi-injection HA viscosupplement for OA knee pain. Competitors include Sanofi (SYNVISC), Zimmer Biomet (Gel-One), and Johnson & Johnson (ORTHOVISC). Market share data is difficult to pinpoint exactly, but ORTHOVISC is a player in the multi-injection HA market.
- HYALOFAST: A resorbable scaffold for cartilage regeneration. Competitors include DePuy Synthes Mitek Sports Medicine (MAKOplasty), and Smith+Nephew. Exact market share is difficult to obtain.
Market Dynamics
Industry Overview
The medical technology industry is characterized by innovation, regulatory hurdles, and competition. The regenerative medicine segment is growing, driven by an aging population and demand for minimally invasive procedures.
Positioning
Anika Therapeutics Inc. is positioned as a specialty player in the regenerative medicine space, focusing on HA-based therapies and surgical solutions. Its competitive advantage lies in its established product portfolio and focus on specific therapeutic areas.
Total Addressable Market (TAM)
The total addressable market for Anika's products is estimated in the billions of dollars, encompassing OA pain management, soft tissue repair, and regenerative medicine. Anika is positioned to capture a portion of this TAM through product innovation and market expansion.
Upturn SWOT Analysis
Strengths
- Established product portfolio
- Focus on regenerative medicine
- Strong brand reputation
- Proprietary technologies
- Experienced management team
Weaknesses
- Reliance on HA-based products
- Limited geographic diversification
- Vulnerable to competition
- Dependence on regulatory approvals
- Higher R&D Expense
Opportunities
- Expanding into new therapeutic areas
- Acquiring complementary technologies
- Increasing geographic reach
- Developing innovative products
- Partnerships to develop pipeline
Threats
- Increased competition
- Regulatory changes
- Economic downturn
- Patent expirations
- Product liability claims
Competitors and Market Share
Key Competitors
- SNY
- ZBH
- JNJ
Competitive Landscape
Anika faces competition from large, established medical device companies and smaller, specialized players. Its advantages include its proprietary technologies and focus on specific therapeutic areas. Disadvantages include its smaller size and limited geographic reach.
Major Acquisitions
Parcus Medical, LLC
- Year: 2019
- Acquisition Price (USD millions): 26
- Strategic Rationale: Expanded Anika's portfolio into sports medicine and arthroscopic solutions.
Growth Trajectory and Initiatives
Historical Growth: Anika Therapeutics Inc. has experienced moderate growth in the past, driven by product sales and strategic acquisitions.
Future Projections: Analyst estimates project continued growth for Anika Therapeutics Inc., driven by new product launches and market expansion. These vary from 2% to 5%.
Recent Initiatives: Recent initiatives include new product development, strategic acquisitions, and market expansion efforts.
Summary
Anika Therapeutics Inc. is a specialty medical technology company focused on regenerative medicine. While it has strong brand recognition and proprietary technologies, it faces challenges from larger competitors and regulatory hurdles. Its focus on HA-based therapies gives it a foothold in the market, but diversification and geographic expansion are important for future growth. Anika needs to keep an eye out for patent expirations.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Market Research Reports
- Earnings Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share data are estimates and may vary. Financial performance is based on past results and does not guarantee future performance.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Anika Therapeutics Inc
Exchange NASDAQ | Headquaters Bedford, MA, United States | ||
IPO Launch date 1993-04-29 | President, CEO & Director Dr. Cheryl Renee Blanchard Ph.D. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 288 | Website https://www.anika.com |
Full time employees 288 | Website https://www.anika.com | ||
Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products include Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide short-and long-term pain relief. The company's joint preservation and restoration product family comprises orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants to treat upper and lower extremity orthopedic conditions. In addition, the company offers non-orthopedic products comprising HA-based products for Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier for use after abdominal-pelvic surgeries; and Hyalomatrix for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.